Avel eCare Positions Technology as a Lifeline for Hospital Viability and Patient Care
Innovative virtual care services are transforming ICU management and ensuring rural hospitals keep their doors open.
SIOUX FALLS, SD / ACCESS Newswire / June 3, 2025 / As hospital systems nationwide continue to grapple with staff shortages, rising costs, and the ever-pressing demand to improve patient outcomes, Avel eCare is redefining how technology can transform healthcare delivery. Through its innovative telemedicine solutions, including 24/7 ICU support, Avel eCare is helping hospitals increase their patient throughput, reduce costly transfers, and improve revenue cycle management-ultimately enabling more facilities to stay viable and serve their communities.
'Our Critical Care service is about more than just monitoring,' says Keith Holt, Director of Acute Inpatient Services and Senior Care at Avel eCare. 'We bring continuous, comprehensive ICU support to hospitals of all sizes, using real-time data from EMRs, bedside monitors, and integrated systems to deliver expert care and improve patient outcomes-no matter where they are.' ( Extended interview available here )
From major health systems to critical access hospitals with only a handful of ICU beds, Avel's technology makes intensivist-level care accessible at the push of a button. These virtual partnerships allow hospitals to retain patients they might otherwise transfer, directly impacting their census and bottom line.
'We've reduced ICU length of stay by an average of 1.75 days and ventilator hours by 13 per patient,' Holt adds. 'When you look at that over time, across dozens or hundreds of patients, the cost savings-and patient impact-are massive.'
That impact is measurable. On average, Avel-supported hospitals reduce total hospital stays by 1.55 days, saving $3,548 per admission, and ICU stays by 1.75 days, yielding $5,688 in savings. Each patient who avoids transfer means approximately $15,000 in retained revenue for the hospital. These efficiencies add up quickly, helping facilities of all sizes, from rural hospitals to large urban systems, improve both outcomes and financial performance.
At the core of Avel's approach is the intersection of innovation and clinical expertise. 'Our goal is to let technology fade into the background so our clinical teams can focus on what they do best: caring for patients,' says Mandy Bell, Vice President of Product Innovation. 'We've developed one-touch access, real-time data integration, and even in-ambulance telehealth-all tested in our in-house Innovation Lab to ensure seamless, stress-free support.'
As hospitals look to improve their revenue cycle and operational efficiency, telemedicine has become a strategic asset. 'Technology isn't a luxury-it's a necessity,' says Dr. Kelly Rhone, Chief Medical Officer at Avel eCare. 'We're not replacing hospital staff. We're extending them. And in many cases, we're the reason physicians and nurses stay in their roles longer-because they know they're supported.'
Avel eCare's impact is more than clinical-it's existential. In an era where rural and urban hospitals alike face closure, Avel's suite of services gives facilities the tools they need to stay open and deliver quality care. Whether it's through ICU support, hospitalist backup, or emergency response integration, Avel is proving that innovation, when paired with deep clinical expertise, can help secure the future of healthcare.
'Every second counts in patient care,' Bell says. 'With the right technology and team, hospitals don't just survive-they thrive.'
About Avel eCare
With over 30 years of telehealth leadership, Avel eCare delivers expert care when and where it's needed. From ICU and emergency services to behavioral health, hospitalist coverage, and beyond, Avel partners with health systems to extend care teams, improve outcomes, and support long-term sustainability. Learn more at www.avelecare.com.
For media inquiries, interview clips and video assets, please contact:
Jessica Gaikowski
Avel eCare
[email protected]
SOURCE: Avel eCare
press release
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
a day ago
- Yahoo
Opinion: Science is Utah's quiet engine — don't stall it with cuts to important funding
Science quietly powers Utah's prosperity. From lifesaving diagnostics at ARUP Laboratories and cutting-edge biotech startups to clean energy research at Utah State and drought-resistant crops developed through university partnerships, science is behind much of what makes life in Utah better, longer and more secure. In 2024, the National Institutes of Health (NIH) awarded over $300 million to Utah institutions. That funding supported thousands of jobs, helped launch companies, and enabled groundbreaking research in everything from cancer treatments to Alzheimer's to rare disease therapies. Public health advances that benefit every Utahn — urban or rural — almost always begin through federally funded research. But now, that progress is in jeopardy. Proposed cuts and restrictions to NIH funding could have devastating effects on Utah's research institutions and economy. The plan to slash NIH's overall budget by nearly half, coupled with a proposal to reduce the indirect cost reimbursement to universities from around 50% to 15%, would mean far less money to cover the real costs of doing science. Basics like lab space, utilities, data storage and administrative support aren't luxuries — they're the infrastructure that makes research possible. For public universities like the University of Utah and Utah State, this isn't just a budget concern. It's a structural threat. Without adequate indirect cost support, universities would either have to drastically scale back research activity or shift the financial burden to students and state taxpayers. Both options would weaken Utah's competitive edge in science and technology. The consequences would ripple far beyond campus. Utah is known for its 'Industry' motto — a title that honors the resourcefulness and hard work that built our communities. Today, that industrious spirit thrives in our biotech labs, clean tech startups and health research centers. But industries can't thrive without innovation. Utah's life sciences sector depends on a steady pipeline of NIH-supported talent and discoveries emerging from research. Companies like Recursion, Myriad Genetics and BioFire Diagnostics thrive because of academic partnerships and access to skilled graduates. Pulling funding would slow innovation and shrink the talent pool. But it's not just about economics. It's about people. NIH funding supports clinical trials that help Utah families battling cancer. It funds suicide prevention programs in our schools, mental health outreach in rural counties, and pediatric care innovations at Primary Children's Hospital (PCH). It supports research for Native American communities and families dealing with chronic conditions like diabetes and asthma. Without that funding, many of these programs would disappear. I've seen the impact of public health investment firsthand. After I tested positive for latent tuberculosis as a student, I received free weekly treatment and health monitoring through the Utah County Health Department. It was science-backed care, delivered through a local system supported by federal resources. Without that treatment, I could have developed active tuberculosis — a threat not just to me but also to others. The system worked because it was built on scientific research and proactive policy. That kind of safety net doesn't happen without sustained funding. Furthermore, my nephew, Wesley, was cared for at PCH when he was just four months old. He was diagnosed with polyarteritis nodosa, a rare autoimmune disease that causes inflammation and damage to the heart. The NIH not only funds various programs at PCH but also was crucial to backing the science that led to properly diagnosing and saving Wesley. These cuts hurt the next generation. Graduate students and early career scientists — many of whom come from Utah — rely on federal research grants to get their start. If funding dries up, so do those opportunities. We risk losing promising young minds to other careers or other countries. This is not a partisan issue. Scientific progress should never be about politics. Every Utahn benefits from the medications they take, the clean water they drink, the safe food they eat and the medical care they receive. All of these are underpinned by science. Restricting it weakens our shared safety net and quality of life. Utah is built on hard work, innovation and foresight. Cutting science funding now would undermine the very foundation that allows us to adapt, compete and care for our communities. Science works for Utah — let's keep it that way.
Indianapolis Star
a day ago
- Indianapolis Star
Moderna Announces Update on Investigational Pandemic Influenza Program
Phase 1/2 H5 avian flu vaccine study shows positive interim results Company has been notified that HHS will terminate Moderna's award for late-stage development of pre-pandemic influenza vaccines CAMBRIDGE, MA / ACCESS Newswire Moderna, Inc. (NASDAQ:MRNA) today announced positive interim data from a Phase 1/2 clinical study (NCT05972174) evaluating the safety and immunogenicity of its investigational pandemic influenza vaccine, mRNA-1018, in approximately 300 healthy adults aged 18 years and older. The interim results focus on a vaccine candidate targeting the H5 avian influenza virus subtype. The Company had previously expected to advance the program to late-stage development with the U.S. Department of Health and Human Services (HHS); however, today Moderna received notice that HHS will terminate the award for the late-stage development and right to purchase pre-pandemic influenza vaccines. 'While the termination of funding from HHS adds uncertainty, we are pleased by the robust immune response and safety profile observed in this interim analysis of the Phase 1/2 study of our H5 avian flu vaccine and we will explore alternative paths forward for the program,' said Stéphane Bancel, Chief Executive Officer of Moderna. 'These clinical data in pandemic influenza underscore the critical role mRNA technology has played as a countermeasure to emerging health threats.' The Phase 1/2 study evaluated a two-dose regimen of Moderna's investigational avian influenza vaccine. mRNA-1018 demonstrated a rapid, potent and durable immune response. At baseline, pre-existing immunity was minimal, with only 2.1% of participants showing hemagglutination inhibition (HAI) antibody titers ≥1:40, an HAI titer considered to correlate with protection. At Day 43, three weeks after the second vaccination, 97.8% of participants achieved titers ≥1:40 with a 44.5-fold increase of titers from baseline. The investigational vaccine was generally well-tolerated, with no dose-limiting tolerability concerns observed. Most solicited adverse reactions were Grade 1 or 2 and did not increase significantly with number of doses or between first and second doses. Further data is expected to be submitted for presentation at an upcoming scientific meeting. Moderna will explore alternatives for late-stage development and manufacturing of the H5 program consistent with the Company's strategic commitment to pandemic preparedness. About Moderna Moderna is a leader in the creation of the field of mRNA medicine. Through the advancement of mRNA technology, Moderna is reimagining how medicines are made and transforming how we treat and prevent disease for everyone. By working at the intersection of science, technology and health for more than a decade, the company has developed medicines at unprecedented speed and efficiency, including one of the earliest and most effective COVID-19 vaccines. Moderna's mRNA platform has enabled the development of therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases and autoimmune diseases. With a unique culture and a global team driven by the Moderna values and mindsets to responsibly change the future of human health, Moderna strives to deliver the greatest possible impact to people through mRNA medicines. For more information about Moderna, please visit and connect with us on X (formerly Twitter), Facebook, Instagram, YouTube and LinkedIn. Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including statements regarding: the clinical development of mRNA-1018, the safety and immunogenicity data from the Phase 1/2 study; the cancellation of the development contract for Moderna's pandemic flu program by the U.S. Department of Health and Human Services; and the exploration of alternative paths for development of the vaccine program. The forward-looking statements in this press release are neither promises nor guarantees, and you should not place undue reliance on these forward-looking statements because they involve known and unknown risks, uncertainties, and other factors, many of which are beyond Moderna's control and which could cause actual results to differ materially from those expressed or implied by these forward-looking statements. These risks, uncertainties, and other factors include, among others, those risks and uncertainties described under the heading 'Risk Factors' in Moderna's Annual Report on Form 10-K for the fiscal year ended December 31, 2024, and in subsequent filings made by Moderna with the U.S. Securities and Exchange Commission, which are available on the SEC's website at Except as required by law, Moderna disclaims any intention or responsibility for updating or revising any forward-looking statements contained in this press release in the event of new information, future developments or otherwise. These forward-looking statements are based on Moderna's current expectations and speak only as of the date of this press release. Moderna Contacts Investors: Lavina Talukdar Senior Vice President & Head of Investor Relations +1 617-209-5834 SOURCE: Moderna, Inc. View the original press release on ACCESS Newswire
Indianapolis Star
a day ago
- Indianapolis Star
Divorced and Facing IRS Collection? Clear Start Tax Outlines How Innocent Spouse Relief Could Save You Thousands
Clear Start Tax Explains How Divorced Taxpayers Can Escape IRS Liability for a Former Spouse's Mistakes IRVINE, CA / ACCESS Newswire Divorce can be complicated enough without the added stress of IRS debt. Yet every year, countless divorced Americans are shocked to discover they're on the hook for a former spouse's tax liabilities – often for mistakes they didn't know about. According to Clear Start Tax, a leading national tax resolution firm, the IRS's Innocent Spouse Relief program can offer a powerful – and often overlooked – solution. When Divorce Leaves Taxpayers Facing a Former Spouse's Mistakes Many taxpayers assume that a divorce decree automatically separates their financial obligations. But under joint tax returns, the IRS can pursue either spouse for the full amount owed, including taxes, penalties, and interest. That means years after a divorce, one spouse may face wage garnishment, bank levies, or collection notices for a tax bill they had no role in creating. 'We've worked with clients blindsided by IRS letters years after their divorce,' said the Head of Client Solutions at Clear Start Tax. 'Innocent Spouse Relief can be a lifeline in these cases – but most people don't even realize it exists.' Who Qualifies for Innocent Spouse Relief? Clear Start Tax explains that the IRS looks at several key factors when reviewing Innocent Spouse claims: The tax understatement was due to the other spouse's error (such as unreported income or inflated deductions). The innocent spouse didn't know, and had no reason to know, about the issue at the time. Holding the innocent spouse liable would be unfair or create hardship. The innocent spouse applies within the IRS's filing window (generally two years from first collection notice). Why the Right Approach Is Essential for Approval While the program offers powerful protection, Clear Start Tax emphasizes that success depends on a careful application and thorough documentation. Missing deadlines, submitting incomplete paperwork, or misunderstanding eligibility rules can lead to denial, leaving taxpayers exposed to the full debt. 'Innocent Spouse Relief isn't just a form-it's a carefully built case,' said the Head of Client Solutions at Clear Start Tax. 'We work closely with our clients to present the strongest possible application, so they can move forward without being burdened by a former partner's tax mistakes.' How Clear Start Tax Helps Divorced Taxpayers Regain Control Clear Start Tax offers a hands-on, strategic approach to Innocent Spouse claims and other tax resolution programs: Comprehensive case reviews to assess eligibility and strengthen claims Detailed preparation of IRS applications with supporting evidence Direct IRS communication and negotiation on the client's behalf Post-resolution guidance to maintain compliance and peace of mind About Clear Start Tax Clear Start Tax is a full-service tax liability resolution firm that serves taxpayers throughout the United States. The company specializes in assisting individuals and businesses with a wide range of IRS and state tax issues, including back taxes, wage garnishment relief, IRS appeals, and offers in compromise. Clear Start Tax helps taxpayers apply for the IRS Fresh Start Program, providing expert guidance in tax resolution. Fully accredited and A+ rated by the Better Business Bureau, the firm's unique approach and commitment to long-term client success distinguish it as a leader in the tax resolution industry. Need Help With Back Taxes? Click the link below: Contact Information Clear Start Tax Corporate Communications Department seo@ (949) 535-1627 SOURCE: Clear Start Tax View the original press release on ACCESS Newswire
